ULTRAGENYX PHARMACEUTICAL INC. Finite-Lived Intangible Asset, Expected Amortization, Year Four
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Finite-Lived Intangible Asset, Expected Amortization, Year Four of $7.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour · last filed 2026-02-18
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $7.00K.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $6.28M.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $4.46M.
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $3.74M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Four |
|---|---|
| 2025-12-31 | $7.00K 10-K · filed 2026-02-18 |
| 2024-12-31 | $6.28M 10-K · filed 2025-02-19 |
| 2023-12-31 | $4.46M 10-K · filed 2024-02-21 |
| 2022-12-31 | $3.74M 10-K · filed 2023-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |